Membrane type 1 matrix metalloproteinase promotes LDL receptor shedding and accelerates the development of atherosclerosis
Elevated plasma LDL cholesterol levels increase the risk of atherosclerotic cardiovascular disease. Here, the authors show that inhibition of MT1-MMP reduces plasma LDL cholesterol levels and the risk of atherosclerosis, indicating the potential of MT1-MMP inhibition as a lipid-lowering therapy.
Main Authors: | Adekunle Alabi, Xiao-Dan Xia, Hong-Mei Gu, Faqi Wang, Shi-Jun Deng, Nana Yang, Ayinuer Adijiang, Donna N. Douglas, Norman M. Kneteman, Yazhuo Xue, Li Chen, Shucun Qin, Guiqing Wang, Da-Wei Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-03-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-021-22167-3 |
Similar Items
-
Identification of amino acid residues in the ligand binding repeats of LDL receptor important for PCSK9 binding[S]
by: Shi-jun Deng, et al.
Published: (2019-03-01) -
Increased LDL susceptibility to oxidation accelerates future carotid artery atherosclerosis
by: Aoki Toshinari, et al.
Published: (2012-01-01) -
METALLOPROTEINASE AND ATHEROSCLEROSIS
by: Ya. V. Polonskaya, et al.
Published: (2017-09-01) -
Endostatin binds biglycan and LDL and interferes with LDL retention to the subendothelial matrix during atherosclerosis
by: Xiaokun Zeng, et al.
Published: (2005-09-01) -
Matrix Metalloproteinases in COPD and atherosclerosis with emphasis on the effects of smoking.
by: M Kraen, et al.
Published: (2019-01-01)